Jupiter Topco LLC Makes New $112.19 Million Investment in Edwards Lifesciences Corporation $EW

Jupiter Topco LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,240,222 shares of the medical research company’s stock, valued at approximately $112,188,000. Jupiter Topco LLC owned approximately 0.22% of Edwards Lifesciences as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the third quarter worth $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the fourth quarter worth $26,000. RMG Wealth Management LLC purchased a new position in Edwards Lifesciences during the first quarter valued at $26,000. Finally, TrinityBridge Ltd purchased a new position in Edwards Lifesciences during the second quarter valued at $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,425 shares of company stock worth $219,199. Insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on EW. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Mizuho upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Finally, Evercore reiterated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Price Performance

EW opened at $90.93 on Thursday. The stock has a 50-day moving average price of $89.43 and a 200-day moving average price of $84.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm has a market cap of $52.36 billion, a PE ratio of 52.26, a P/E/G ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.